Governmental or Regulatory Activity – Page 8

Ex-HHS Workers Accuse Trump Administration of Using Flawed Data to Justify Mass Firings

5 months ago talkbio0Tagged Agencies, CHARGE Syndrome, disability services, firings, Medicare, Project, public servants, Trump administration

HHS firings; Trump administration; federal workforce; flawed data; Project 2025; agency cuts; disability services; Medicare; public servants

RFK Jr. Ends CDC Covid Vaccine Recommendations for Healthy Children and Pregnant Women

5 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), CHARGE Syndrome, Child, COVID19 (disease), Pregnant Women, public health policy, Recommendation, RFK Jr., Secretary, Vaccines

RFK Jr.; COVID-19 vaccine; recommendations; children; pregnant women; CDC; HHS Secretary; public health policy

About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds

5 months ago talkbio0Tagged Biological Factors, CBER, CDER, Drug Approval Process, drug review, layoffs, Staff, Trump administration, United States Food and Drug Administration

FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process

Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.

5 months ago talkbio0Tagged Beak, Budgets, CBO, healthcare changes, Medicare, reconciliation, Sequestration, Transplant Registry Unified Management Program

Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report

FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation

5 months ago talkbio0Tagged Advisory Committees, Availability of, COVID19 (disease), formula update, JN.1-lineage, KP.2 strain, United States Food and Drug Administration, Vaccines

FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo

5 months ago talkbio0Tagged Advisory Committees, enzalutamide, expansion, Inhibitor, Labels (device), Malignant neoplasm of prostate, mCRPC, PARP1 gene, Pfizer, talazoparib, Talzenna, unanimous vote, United States Food and Drug Administration

FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote

FDA Advisory Committee Splits Votes on Genentech and J&J Cancer Drugs

5 months ago talkbio0Tagged Advisory Committees, applicability, cancer drugs, Clinical Trials, Columvi, genentech, J&J, ODAC, STARGLO, United States Food and Drug Administration, Voting

FDA; advisory committee; Genentech; J&J; cancer drugs; Columvi; ODAC; clinical trials; diffuse large B-cell lymphoma; applicability; STARGLO; voting

FDA Delays Decision on Biohaven’s Troriluzole for Rare Disease, Plans Advisory Committee Review

6 months ago talkbio0Tagged Advisory Committees, Ataxia, Spinocerebellar, Biohaven, Deferred, disease drug, Extension, Infrequent, Neurodegenerative Disorders, PDUFA, Troriluzole, United States Food and Drug Administration

Biohaven; FDA delay; troriluzole; spinocerebellar ataxia (SCA); rare disease drug; PDUFA extension; advisory committee; neurodegenerative disease

RFK Jr. Defends HHS Staff Cuts and Reorganization at House and Senate Hearings

6 months ago talkbio0Tagged Budgets, CHARGE Syndrome, Congress (U.S. Legislature), health coverage, HELP Committee, House Appropriations Committee, Medicaid, reorganization, RFK Jr., Senate, Staff

RFK Jr.; HHS; staff cuts; reorganization; Congress; House Appropriations Committee; Senate HELP Committee; budget cuts; Medicaid; health coverage

White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain

6 months ago talkbio0Tagged Comparison, Drug Prescriptions, drug price, Favored, global price, Nation, Pharmaceutical Policy, Trump administration, U.S., White House

Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy